A new systematic review and meta-analysis examines schizophrenia substance use treatment interventions, focusing on psychological and psychosocial approaches for this challenging dual-diagnosis population. The research addresses a critical evidence gap for patients who comprise over 40% of people with schizophrenia but are often excluded from clinical trials.